These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 10566803)

  • 1. Release potency tests of hepatitis vaccines.
    Descamps J; Mary A; Rommel E; Anhoury ML; De Neys R; Duchêne M
    Dev Biol Stand; 1999; 101():289-94. PubMed ID: 10566803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the antibody response in humans with a new inactivated hepatitis A vaccine.
    Vidor E; Xueref C; Blondeau C; Bajard A; Francon A; Goudeau A; Peyron F; Brasseur P; Zuckerman A
    Biologicals; 1996 Sep; 24(3):235-42. PubMed ID: 8978923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Reactivity and immunogenicity of Havrix 360 vaccine for hepatitis A].
    Borcić B; Kovac S; Mihaljević I; Dobrovsak-Sourek V; Ljubicić M
    Lijec Vjesn; 1996; 118(7-8):162-4. PubMed ID: 8965633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivated virosome hepatitis A vaccine.
    D'Hondt E; Delem A
    Lancet; 1994 May; 343(8906):1165-6. PubMed ID: 7910259
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatitis A-vaccines: a comparison between three methods of antigen determination.
    Burkhardt F; Glück R; Finkel-Jimenez B; Brantschen S
    Dev Biol Stand; 1996; 86():129-35. PubMed ID: 8785942
    [No Abstract]   [Full Text] [Related]  

  • 6. In vitro versus in vivo concordance: a case study of the replacement of an animal potency test with an immunochemical assay.
    Schofield T
    Dev Biol (Basel); 2002; 111():299-304. PubMed ID: 12678253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings.
    André FE; D'Hondt E; Delem A; Safary A
    Vaccine; 1992; 10 Suppl 1():S160-8. PubMed ID: 1335652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults.
    Van Damme P; Leroux-Roels G; Law B; Diaz-Mitoma F; Desombere I; Collard F; Tornieporth N; Van Herck K
    J Med Virol; 2001 Sep; 65(1):6-13. PubMed ID: 11505437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunogenicity of vaccines against viral hepatitis A and B in the population above 40 years of age -- impact of risk factors].
    Chlíbek R; Smetana J; Sindelár R; Cecetková B; Prymula R; Kohl I
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):119-28. PubMed ID: 17900060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A redoubtable obstacle to a hepatitis C vaccine.
    Koff RS
    Gastroenterology; 1993 Apr; 104(4):1228-9. PubMed ID: 8385045
    [No Abstract]   [Full Text] [Related]  

  • 11. [Comparison of immunogenicity and safety of Engerix B and Twinrix vaccine].
    Gałaj A; Grześk G; Borys D; Durmowicz A; Grześk E; Szadujkis-Szadurski L
    Wiad Lek; 2004; 57(5-6):217-20. PubMed ID: 15518064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of a combined hepatitis A and B vaccine in healthy young adults.
    Knöll A; Hottenträger B; Kainz J; Bretschneider B; Jilg W
    Vaccine; 2000 Apr; 18(19):2029-32. PubMed ID: 10706965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children.
    Kanra G; Yalçin SS; Ceyhan M; Yurdakök K
    Turk J Pediatr; 2000; 42(2):105-8. PubMed ID: 10936974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production, quality control and characterization of an inactivated hepatitis A vaccine.
    Peetermans J
    Vaccine; 1992; 10 Suppl 1():S99-101. PubMed ID: 1335671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute hepatitis A in a traveler who had received preexposure inactivated hepatitis A virus vaccine.
    Kurup A; San LM; Yew WS
    Clin Infect Dis; 1999 Jun; 28(6):1324-5. PubMed ID: 10451178
    [No Abstract]   [Full Text] [Related]  

  • 16. Persistence of vaccine-induced antibody to hepatitis A virus.
    Wiedermann G; Ambrosch F; André FE; D'Hondt E; Delem A; Safary A
    Vaccine; 1992; 10 Suppl 1():S129-31. PubMed ID: 1335643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Safety and immunogenicity of Bilive combined hepatitis A and B vaccine].
    Zhao YL; Chen YG; Li J; Han GX; Tian C; Liang JL; Li G; Wang ZG; Zhu YG; Tian ZN; Zhang HY; Wan ZJ; Liang ZL; Bi SL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):470-3. PubMed ID: 15231119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis A and B vaccines in children.
    Lieberman JM; Greenberg DP
    Adv Pediatr Infect Dis; 1996; 11():333-63. PubMed ID: 8718466
    [No Abstract]   [Full Text] [Related]  

  • 19. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines.
    Van Herck K; Beutels P; Van Damme P; Beutels M; Van den Dries J; Briantais P; Vidor E
    J Med Virol; 2000 Jan; 60(1):1-7. PubMed ID: 10568755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B vaccine.
    Capiau C
    Dev Biol Stand; 1998; 96():127-9. PubMed ID: 9890526
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.